Olmesartán/Amlodipino Cinfa (Olmesartan Medoxomil, Amlodipine)

Olmesartan/Amlodipine is used in the management of high blood pressure, acting on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: helps achieve target blood pressure when monotherapy is insufficient.
• Hypertension with concomitant cardiovascular risk: provides additional blood‑pressure reduction and may improve overall cardiovascular risk profile.
• Resistant hypertension: used as part of a multi‑drug regimen to attain adequate control.
• Hypertension in elderly patients: offers once‑daily dosing convenience and tolerability.
• Hypertension in patients with metabolic syndrome: assists in blood‑pressure control without adverse metabolic effects.

• Olmesartan Medoxomil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect reduces systemic vascular resistance and lowers blood pressure more effectively than either component alone.

Olmesartan/Amlodipine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Peripheral edema: mild swelling, usually of the ankles.
• Headache: transient, often resolves with continued therapy.
• Dizziness: related to blood‑pressure lowering.
• Flushing: brief sensation of warmth.
• Fatigue: general tiredness.
• Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects

• Angio‑edema: swelling of face, lips, tongue, or throat.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: abnormal liver enzymes.
• Myocardial infarction: rare but reported in susceptible patients.
• Renal impairment: worsening kidney function.
• Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Olmesartan/Amlodipine, clinicians should consider several safety aspects.

• Renal function: assess baseline kidney function and monitor periodically.
• Hepatic function: evaluate liver enzymes before initiation.
• Electrolyte balance: watch for potassium abnormalities, especially with concomitant diuretics.
• Pregnancy: avoid use; drug is contraindicated in pregnancy.
• Elderly patients: start at lower dose and monitor for hypotension.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase amlodipine levels.
• NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause additive blood‑pressure lowering.\n- Lithium: increased risk of lithium toxicity.
• Rifampicin: may reduce olmesartan exposure.
• Diuretics: may enhance hypotensive effect.
• Alcohol: can potentiate dizziness and hypotension.